Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
27
27 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- HRS-5965Phase 36 trials
Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
- HSK39297Phase 35 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- NTQ5082Phase 34 trials
Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy
- SCTC21CPhase 34 trials
Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)
- JADE101Phase 32 trials
Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy
- BHV-1400Phase 31 trial
Biohaven Therapeutics Ltd. · IgA Nephropathy
- SC0062Phase 31 trial
Biocity Biopharmaceutics Co., Ltd. · IgA Nephropathy (IgAN)
- SefaxersenRO7434656Phase 31 trial
Roche (Genentech) · Primary IgA Nephropathy
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- SHR-2173Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy
- HSK39297 200mgQDPhase 23 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- HS-10542Phase 22 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
- HSK39297 300mgQDPhase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- SGB-9768Phase 22 trials
Suzhou Sanegene Bio Inc. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy
- SLN12140Phase 22 trials
Linno Pharmaceuticals, Inc. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria (PNH)
- XH-S003Phase 22 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy
- ADX-097Phase 21 trial
Akebia Therapeutics · IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
- ARGX-121Phase 21 trial
argenx · Immunoglobulin A Nephropathy (IgAN)
- CM338Phase 21 trial
Keymed Biosciences Co.Ltd · IgA Nephropathy
- EVER001Phase 21 trial
Everest Medicines (China) Co.,Ltd. · Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS)
- QLS7305Phase 21 trial
Qilu Pharmaceutical Co., Ltd. · IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G)
- RG002C0106Phase 21 trial
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. · IgA Nephropathy (IgAN)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.